1. Home
  2. IMNM vs VERA Comparison

IMNM vs VERA Comparison

Compare IMNM & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Immunome Inc.

IMNM

Immunome Inc.

HOLD

Current Price

$25.64

Market Cap

2.5B

Sector

Health Care

ML Signal

HOLD

Logo Vera Therapeutics Inc.

VERA

Vera Therapeutics Inc.

HOLD

Current Price

$31.54

Market Cap

3.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IMNM
VERA
Founded
2006
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.5B
3.0B
IPO Year
2020
2021

Fundamental Metrics

Financial Performance
Metric
IMNM
VERA
Price
$25.64
$31.54
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
10
10
Target Price
$32.80
$81.30
AVG Volume (30 Days)
1.1M
2.0M
Earning Date
05-08-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
51.40
N/A
EPS
N/A
N/A
Revenue
$6,941,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$1,127.34
$472.48
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.67
$19.25
52 Week High
$27.65
$56.05

Technical Indicators

Market Signals
Indicator
IMNM
VERA
Relative Strength Index (RSI) N/A N/A
Support Level N/A N/A
Resistance Level N/A N/A
Average True Range (ATR) 0.00 0.00
MACD 0.00 0.00
Stochastic Oscillator 0.00 0.00

Price Performance

Historical Comparison
IMNM
VERA

About IMNM Immunome Inc.

Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.

About VERA Vera Therapeutics Inc.

Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.

Share on Social Networks: